Literature DB >> 2525323

Acute hemodynamic effects of single-dose nicorandil in coronary artery disease.

D J Coltart1, M Signy.   

Abstract

Fifteen patients undergoing routine cardiac catheterization for investigation of chest pain were given a single dose of 40 mg of nicorandil either sublingually (8 patients) or orally (7 patients). Fourteen patients had angina (11 effort, 3 atypical) and 1 had palpitations but all had normal left ventricular (LV) function (mean LV end-diastolic pressure 7.4 mm Hg). Hemodynamic evaluations and plasma drug concentrations were performed at baseline and 5, 15, 30, 45 and 60 minutes after dosing. In addition, venous compliance was determined at baseline, 15 and 45 minutes using forearm venous occlusion plethysmography. Significant (p less than 0.05) central and peripheral hemodynamic changes occurred within 15 minutes. A reduction in preload was apparent from a decrease in LV end-diastolic pressure (from 7.4 +/- 1.7 to -2.6 +/- 1.5 mm Hg [p less than 0.05]) and a simultaneous decrease in mean pulmonary artery pressure (from 10.8 +/- 0.7 to 5.1 +/- 0.6 mm Hg [p less than 0.05]) at 60 minutes after dosing. This reduction in preload may reflect the venous vasodilatory activity of the drug as indicated by significant (p less than 0.05) increases in venous capacitance at 15 and 45 minutes. Total peripheral resistance decreased to a maximum of 19% (p less than 0.05) at 30 minutes and then began to return toward baseline. This effect in reducing afterload led to a substantial decrease (p less than 0.05) in systolic and diastolic aortic blood pressures, which was maximal at 45 minutes (34 and 21%, respectively). Transient increases in heart rate (p less than 0.05) and cardiac contractility indexes (p less than 0.05) were also observed.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2525323     DOI: 10.1016/0002-9149(89)90202-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  12 in total

1.  [Nicorandil: acute hemodynamic effects of 2 different oral doses of a potassium channel opener in patients with coronary heart disease].

Authors:  C Bickel; H J Rupprecht; A Tyrtania; J Rörig; J Meyer
Journal:  Med Klin (Munich)       Date:  1999-02-15

Review 2.  Pharmacology and therapeutic effects of nicorandil.

Authors:  M Kinoshita; K Sakai
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

Review 3.  Nicorandil. An updated review of its use in ischaemic heart disease with emphasis on its cardioprotective effects.

Authors:  A Markham; G L Plosker; K L Goa
Journal:  Drugs       Date:  2000-10       Impact factor: 9.546

4.  Double-blind comparison of the acute effects of two relevant doses of oral nicorandil on central hemodynamics, left ventricular function, and myocardial contractility.

Authors:  A Baumbach; U Braun; G Döring; K K Haase; W Voelker; K R Karsch
Journal:  Cardiovasc Drugs Ther       Date:  1995-03       Impact factor: 3.727

Review 5.  Potassium channel openers: clinical applications in ischemic heart disease--overview of clinical efficacy of nicorandil.

Authors:  C Knight; H Purcell; K Fox
Journal:  Cardiovasc Drugs Ther       Date:  1995-03       Impact factor: 3.727

6.  A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris.

Authors:  S Di Somma; V Liguori; M Petitto; A Carotenuto; D Bokor; O de Divitiis; M de Divitiis
Journal:  Cardiovasc Drugs Ther       Date:  1993-02       Impact factor: 3.727

7.  Pharmacokinetics of nicorandil in patients with normal and impaired renal function.

Authors:  M Molinaro; G Villa; M B Regazzi; A Salvadeo; S Segagni; R Rondanelli; E Sartirana
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 8.  Nicorandil. A review of its pharmacology and therapeutic efficacy in angina pectoris.

Authors:  J Frampton; M M Buckley; A Fitton
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

9.  The haemodynamic effects and pharmacokinetics of intravenous nicorandil in healthy volunteers.

Authors:  D L Wolf; J J Ferry; A E Hearron; M O Froeschke; J R Luderer
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

10.  The pharmacokinetics and haemodynamic effects of continuous nicorandil infusion in healthy volunteers.

Authors:  D L Wolf; A E Hearron; C M Metzler; J J Ferry; M O Froeschke; J R Luderer
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.